Acorda Therapeutics Inc (ACORQ)

[cjstocksup]

Awesome day everyone. A least we had a early AM runner with actual news so it was a definite hold all day!

[BoilerRoom]

$ACOR looks good for tomorrow imo

[cash4]

Correction...$1 LMFAO, my options will be on fire tomorrow,

[BoilerRoom]

$ACOR loaded up here

[cash4]

Correction 97.

[cash4]

96 cents aftermarket.

[BoilerRoom]

This good?

[cash4]

Tomorrow will open above $1 easy, today it hit 94 cents.

[Invest-in-America]

ACOR: Hang-on, Peeps!!! She's gonna FLY!!!

[cash4]

Bought last week at 24 cents and today I bought 100 option contracts at 30 cents to expire on Nov 14, I'm set.

[tedgoeseast]

Great swing trade on this one today glad I caught it at the open , for .50 sold @ .855 for a 4210.00 profit good way to start the week

[cash4]

News came yesterday, LMFAO, there's no consolidation, only the fact that the current Market Cap is about the same dollar value as what they have been awarded.

[Spicknspan]

Waiting for a consolidation on this move. Something supported by news.

[cash4]

If it does, my options will go trough the roof.

[Invest-in-America]

ACOR: This should hit circa 300+% UP today, then settle-down significantly before the Close.

[Invest-in-America]

ACOR: Hard to do, but I FORCE myself to wait at least 45-minutes into each day's OPEN before I jump-in to anything!! Doing nice on THIS one now, because I WAITED --- but HARD to discipline one's self to do that. Otherwise, most Peeps get SUCKERED via the morning GAPPERS!!

[tedgoeseast]

This should go back over 1.00 getting 16.5 million in a settlement and have secured access to keep selling their drugs,the market cap Friday was 8.1 million now today they received over two times that amount so this should in the next couple days hit 1.25 ,high for the year was over 4.00

[BoilerRoom]

Wish I could get in these before they run

[Invest-in-America]

ACOR: The WINNER of this trading day!!

[INFINITI]

Break that .6

[INFINITI]

No but short Squeeze looking good I’m loading

[madras50]

any idea of the short position on this? maybe a big squeeze on the way?

[INFINITI]

Nice

[subslover]

Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
October 16 2022 - 04:48PM
Business Wire
Alert
Print
Share On Facebook
$16.5 million to recover past royalties and interest
Cessation of double-digit royalty/supply payments
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC (Nasdaq: ALKS) regarding licensing royalties relating to AMPYRA (dalfampridine). Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, which the Company has already secured.

“This award will allow Acorda to obtain more competitive market rates for the supply of AMPYRA, significantly reducing our cost of goods and meaningfully increasing the product’s value to the company,” said Ron Cohen, M.D., Acorda’s President and CEO. “This will also help Acorda to continue to provide its customary high level of support for Ampyra, ensuring that as many people with MS as possible may benefit from it.”

Acorda filed an arbitration demand with the American Arbitration Association in July 2020 after the parties were unable to resolve their dispute over license and supply royalties following the 2018 expiration of an Alkermes patent relating to AMPYRA.

About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock, including the potential delisting of our common stock from the Nasdaq Global Select Market and actions that we may take, such as a reverse stock split, in order to attempt to maintain such listing; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA or AMPYRA to meet market demand; our reliance on third-party manufacturers for the timely production of commercial supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA or AMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; our ability to satisfy our obligations to distributors and collaboration partners outside the U.S. relating to commercialization and supply of INBRIJA and AMPYRA;competition for INBRIJA and AMPYRA, including increasing competition

[james murphy]

just like all bio at the moment but will turn

[Orphan]

Remember that I said this stock would spike some time ago and now it's reality !!!!!!!!!!!!!!

[INFINITI]

BOOOOM

[Michel]

Acorda Therapeutics EPS beats by $0.13, beats on revenue: Agreement to sell Inbrija in Spain and Germany, in Germany with 5 million in advance

[Michel]

https://www.businesswire.com/news/home/20211109006516/en/

[The Night Stalker]

https://www.stockscores.com/chart.asp?TickerSymbol=%20acor&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[The Night Stalker]

winnerhttps://www.stockscores.com/chart.asp?TickerSymbol=%20acor&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[The Night Stalker]

nice

https://www.stockscores.com/chart.asp?TickerSymbol=%20acor&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[The Night Stalker]

https://www.stockscores.com/chart.asp?TickerSymbol=%20acor&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[Orphan]

This stock is going to spike !!!!! Load up while it's cheap !!!!!!!!

[Orphan]

My opinion has changed, I really am seeing accorda therapeutics going up in the very near future !!!!!!!!!!

[Michel]

Amprya is still doing better than expected and will rack up 75-85 of sales in the US 2021. Famprya is sold by Biogen in Europe and totaled 100 million in 2020. Inbrija has more challenges, but still totaled 24 million sales in 2020 and sales 35-38 in 2021 in the US And now, with the new contract from Spain and the approval of GBA rebates in Germany, Acorda is in an excellent position to negotiate with Biogen or others for other sales outside the US in other countries

[INFINITI]

It’s thin

[Orphan]

This stock is not going to be anything what it used to be !!!!!!!!

[Orphan]

Everyone is taking profit after waiting for years to get anything out of this stock !!!!!!!!

[INFINITI]

Why the suden rise then drop dauum flippers let it run already

[INFINITI]

Cmon let’s gooooo$$$

[INFINITI]

Halt can we gap up huge

[INFINITI]

Boom

[INFINITI]

Can we do a nuro move here

[INFINITI]

Can we do a miro move here

[INFINITI]

Looks good got some let’s roll $$$$

[cjstocksup]

ACOR what fun.

[The Night Stalker]

nah

[Michel]

https://finance.yahoo.com/news/acorda-therapeutics-announces-repayment-convertible-110000484.html


ACOR

[Michel]

https://quantisnow.com/insight/1046468?s=s

Soon the price will pick up all the positive developments:
Biogen Royalties,
Sale of Manufacturing Operations to Catalent

Debt payment,

https://ih.advfn.com/stock-market/NASDAQ/acorda-therapeutics-ACOR/stock-news/85375189/current-report-filing-8-k

new target price $ 10